Article Text

Download PDFPDF
Letter
Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3

Statistics from Altmetric.com

Footnotes

  • Linked articles 212068.

  • Funding The project from which this case is taken was funded by Debio Pharm and their approval has been obtained for this case report (Dr. R. Crabbe). Dr. Jenny Heathcote has commercial associations with the following: Hoffmann LaRoche, Schering-Plough, Axcan-Pharma, Gilead Sciences, GlaxoSmithKline, Human Genome Sciences, Novartis, Idenix, Vertex, Bristol Myers Squibb, Pharmasset, Debiopharm, Boerhinger Ingleheim and Tibotec.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Toronto Western Hospital.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles